



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/783,635	02/20/2004	Ann Marie Schmidt	56613-A JPW/AJM/AAB	1285
7590 11/19/2007				
John P. White Cooper & Dunham LLP 1185 Avenue of the Americas New York, NY 10036				
			EXAMINER	
			EMCH, GREGORY S	
			ART UNIT	PAPER NUMBER
			1649	
			MAIL DATE	DELIVERY MODE
			11/19/2007	PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	Application No. 10/783,635	Applicant(s) SCHMIDT ET AL.	
	Examiner Gregory S. Emch	Art Unit 1649	

**-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) ☒ Responsive to communication(s) filed on 27 August 2007.
- 2a) ☒ This action is **FINAL**.                      2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) ☒ Claim(s) 49,58-62,64-67,69-73 and 76-78 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 49,58-62,64-67,69-73 and 76-78 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                       | 5) <input type="checkbox"/> Notice of Informal Patent Application                       |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

## **DETAILED ACTION**

### ***Response to Amendment***

Claims 32, 51, 63, 68, 74 and 75 have been canceled, claims 49, 58-62, 64-67 and 69 have been amended and new claims 76-78 have been added as requested in the amendment filed on 27 August 2007. Following the amendment, claims 49, 58-62, 64-67, 69-73 and 76-78 are pending in the instant application.

Claims 49, 58-62, 64-67, 69-73 and 76-78 are under examination in the instant office action.

Any objection or rejection of record, which is not expressly repeated in this action has been overcome by Applicants' response and withdrawn.

### ***Claim Rejections - 35 USC § 112***

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

The scope of enablement rejection of claims 49, 58-62, 64-67 and 69-73 under 35 U.S.C. 112, first paragraph is maintained for reasons of record and as set forth below. Furthermore, new claims 76-78 are also subject to the instant rejection. This is because the specification, while being enabling for methods of inhibiting the interaction between AGE and RAGE in kidney failure, for example, with quinine or quinidine, and

thus, treating said disease states, does not reasonably provide enablement for inhibiting the interaction between AGE and RAGE and thus, treating systemic lupus erythematosus or inflammatory lupus nephritis. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to practice the invention commensurate in scope with these claims.

The factors to be considered in determining whether a disclosure would require undue experimentation include (1) the quantity of experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art and, (8) the breadth of the claims. *In re Wands*, 8 USPQ2d, 1400 (CAFC 1988).

In the reply filed on 27 August 2007, Applicants assert, "Applicants further note that the possibility of side effects in a subject following administration of a compound is not a factor to be considered when determining whether a claimed invention is enabled, and therefore the Examiner's remarks regarding the possibility of adverse effects resulting from quinine or quinidine administration are inapplicable to the enablement rejection. Applicants maintain that, based on the specification, one skilled in the art would be able to practice the methods recited in amended claim 49 without undue experimentation."

Applicants' arguments have been fully considered and are not found persuasive.

In the instant case, the possibility of side effects following administration of a compound is indeed a factor to be considered when determining whether the claimed

Art Unit: 1649

invention is enabled, and therefore the Examiner's remarks regarding the possibility of adverse effects resulting from quinine or quinidine administration are indeed applicable to the enablement rejection. The claims require treating a subject with lupus with administration of quinine or quinidine. However, as stated previously, the Bird et al. reference teaches that quinine and quinidine usage has a causal association with lupus associated pathology (entire document, e.g., abstract) and the Rosa-Re et al. reference teaches that quinine induces a lupus-like condition (entire document). If these compounds cause or exacerbate lupus or a lupus-like condition, then the disease is not treated. Since treatment of lupus is required by the claims, it would require undue experimentation to practice the claimed invention, since the invention would not work as evidenced by the prior art. The specification does not provide guidance to overcome the unpredictability of practicing the claimed invention, since Applicants do not disclose any actual examples of quinine or quinidine used to successfully treat lupus.

The test of enablement is not whether any experimentation is necessary, but whether, if experimentation is necessary, it is undue. Due to the large quantity of experimentation necessary to practice the claimed invention, the absence of working examples directed to same, the complex nature of the invention, the state of the prior art which establishes the unpredictability of the claimed methods, and the breadth of the claims, undue experimentation would be required of the skilled artisan to practice the claimed invention in its full scope.

### ***Conclusion***

Art Unit: 1649

No claims are allowed.

**THIS ACTION IS MADE FINAL.** Applicants are reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the mailing date of this final action.

***Advisory Information***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gregory S. Emch whose telephone number is (571) 272-8149. The examiner can normally be reached 9:00 am - 5:30 pm EST (M-F).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Gregory S. Emch/

Gregory S. Emch, Ph.D.  
Patent Examiner  
Art Unit 1649  
07 November 2007

/Elizabeth C. Kemmerer/  
Primary Examiner, Art Unit 1646